Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.44 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EIF2S1 | P05198 | 5/20 | 0.41 |
| ▸ | EIF2AK3 | Q9NZJ5 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369785 | 1.00 | CES2 (0.45) | CES2CES1MEN1KMT2APSEN1 | |
| SCHEMBL7374087 | 0.84 | CES2 (0.47) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL3344127 | 0.84 | CES2 (0.47) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL3344038 | 0.84 | CES2 (0.47) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL4413136 | 0.81 | CES2 (0.55) | CES2CES1KMT2ATSHRSLC6A3 | |
| SCHEMBL4411004 | 0.81 | CES2 (0.55) | CES2CES1KMT2ATSHRSLC6A3 | |
| SCHEMBL4411007 | 0.81 | CES2 (0.55) | CES2CES1KMT2ATSHRSLC6A3 | |
| SCHEMBL7678917 | 0.78 | MEN1 (0.44) | MEN1KMT2ATSHRSLC6A3LMNA | |
| SCHEMBL7678923 | 0.78 | MEN1 (0.44) | MEN1KMT2ATSHRSLC6A3LMNA | |
| SCHEMBL7680429 | 0.78 | MEN1 (0.44) | MEN1KMT2ATSHRSLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1554250-A1 | NOVEL LACTAMS AND USES THEREOF | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004031154-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | CES2 562/4885CES1 249/4885MEN1 1947/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | CES2 2679/4885CES1 974/4885MEN1 4378/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | CES2 500/4885CES1 307/4885MEN1 2194/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | CES2 3031/4885CES1 1320/4885MEN1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.